About the study
PANORAMIC is a clinical study open to those who meet the eligibility criteria described below. The trial can be carried out remotely. This means you can participate from home, with all packs posted directly to you from our trial team. Questionnaires and diaries can be filled out online or if needed via phone call with one of our team.
Please see below to find out more about the study, if your GP practice is participating, and how you can be involved and help in the search for effective treatments for COVID-19.
Thank you for your interest in the PANORAMIC Trial. Paxlovid is now one of the Anti-Viral Treatments within the trial. However, only recruiting GP Hubs are recruiting participants into the Paxlovid arm.
Why are we doing this research?
COVID-19 can cause great suffering, and it stops people from performing their daily activities, affecting their work, education, and caring responsibilities. The risk of complications from COVID-19 is increased in people with underlying health conditions, older people, unvaccinated people, and those in whom the vaccine is less effective. Especially in these people, COVID-19 can sometimes lead to significant medical problems, hospitalisation, and death.
The purpose of this clinical study is to find new treatments that help those suffering with COVID-19 at home and in the community get better quicker and without needing to be treated in hospital. Most people with COVID-19 are treated in the community and so we need to find treatments that are suitable and effective for use early on in the illness.
PANORAMIC aims to find out if new antiviral medicines help to keep people with COVID-19 from needing to be admitted to hospital and help people to get better. All of the treatments in the PANORAMIC trial have been approved by the UK Medicines and Health Care Products Regulatory Agency (MHRA) for use in the study (which regulates the use of all medicines in the UK), and the study is approved by the Health Research Authority.
Purpose of PANORAMIC
A lot of research has focussed on finding treatments for those already sick enough to be admitted to hospital.
PANORAMIC aims to find out if new antiviral treatments helps those with COVID-19 in the community prevents the need for being admitted to hospital and helps people recover quicker.
Exciting new antiviral treatments have been developed that have so far been tested in smaller studies in mostly unvaccinated people. We we do not yet know how effective these treatments will be in the general UK population which is largely vaccinated, so we need to do more studies to find this out.
Those consenting to be part of the study will be randomly selected to either be in a group who receives a course of an antiviral treatment, or a group that doesn’t.
Two different groups are needed so the study team can see any difference in the health of those who received the antiviral treatment compared to those who didn’t.
This information will help the NHS to develop plans for how to best make new antiviral treatments available to patients who would benefit most from this treatment.
Why should I sign up?
No one is obliged to join the study and no one will receive a lesser standard of care by choosing not to join. All participants will be able to access any other NHS care that they would normally expect to receive.
Those who do wish to join the study will be helping in the search for effective treatments for COVID-19 for use in the community. By joining as a participant you will be a critical part of this effort.
This national study aims to quickly generate information which will help the UK's four nations to refine plans for making the antivirals available through normal routes to those who might benefit from them after the study has completed.
Your contribution will help us rapidly produce data about the effectiveness of these antivirals work in vaccinated people, whether you receive the antiviral treatment or not.
Who can join the study?
PANORAMIC is open to anyone that meets the following criteria:
You are currently experiencing COVID-19 symptoms, beginning in the last 5 days;
AND You have had a positive PCR or Lateral Flow test for COVID-19;
AND You are aged 50 or over, or aged 18 or over with a LISTED pre-existing condition (see below).
- Chronic Respiratory disease (including chronic obstructive pulmonary disease (COPD), cystic fibrosis and asthma requiring at least daily use of preventative and/or reliever medication)
- Chronic heart or vascular disease
- Chronic Kidney Disease
- Chronic Liver Disease
- Chronic neurological disease (including dementia, stroke, epilepsy)
- Severe and profound learning disability
- Down’s syndrome
- Diabetes mellitus (Type I or Type II)
- Immunosuppression: primary (e.g. Inherited immune disorders resulting from genetic mutations, usually present at birth and diagnosed in childhood) or Secondary due to disease or treatment (e.g. sickle cell, HIV, cancer, chemotherapy)
- Solid organ, bone marrow and stem cell transplant recipients
- Morbid obesity (BMI > 35)
- Severe mental illness
- Care home resident
- Judged by recruiting clinician or research nurse (registered medical practitioner or trained study nurse) to be clinically vulnerable
How do I sign up?
You may be contacted by a member of the clinical team in a general practice that has been set up to deliver the PANORAMIC trial. They will ask you questions about your interest in joining the study, explain the study to you, check whether this trial is suitable for you, and help you participate in the study.
If you are currently a patient of one of the GP practices listed in the Participating Sites below, you may be eligible for the trial.
What does the trial involve?
If interested, you will be asked some brief questions online or on the telephone to check you are suitable, and provide informed consent to take part.
You can nominate a ‘study partner’ (family, friend, carer) to help you with the study.
Your GP, or a study nurse or doctor, will telephone you to make sure it is safe for you to be in the study, and to check your consent.
You will either receive Usual Care NHS care, or Usual Care plus an antiviral treatment, which can be delivered to you. The study will use a computer programme to decide, based on chance, whether you will get the antiviral treatment we are testing in additional to the care you would normally receive. This process of deciding which group you will be allocated to is completely automated and the trial team cannot alter this.
If allocated to an antiviral treatment plus Usual Care, you will receive a trial pack containing:
- an information booklet;
- a medication card detailing how the medication should be administered, precautions and safety guidance;
- medication appendix providing further information about the treatment (available prior to randomisation as part of the PIS);
- emergency contact card;
- antiviral treatment;
- pregnancy test (only for women of child-bearing potential)
Those randomised to Usual Care without the antiviral treatment will receive an information booklet via email or post.
Women who could possibly become pregnant will be asked to confirm they are not pregnant (a pregnancy test will be delivered with the trial pack). If pregnant, they will be asked to return the study drug and withdraw from the trial. No one who is pregnant or breastfeeding should join the study or take a study treatment.
Taking part in the study will involve answering a few questions online each day for 28 days through the PANORAMIC website, or receiving a phone call from the trial team on days 7, 14, and 28 to speak about your symptoms.
The trial team will also contact you at 3 and 6 months after you started the trial, where we will ask you about any long-term COVID-19 symptoms.
You may withdraw from the trial at any stage by simply contacting the trial team.
If you would like to learn more from the study and join online, please download one of our participant information sheets below: